THE CATALYTIC IMPACT FOUNDATION (CIF)

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.

Massive Bio, is an Artificial Intelligence (AI) powered platform that connects cancer patients and their treating oncologists to clinical trials while enabling pharmaceutical companies to get access to patients, mostly in community practices, and their information to speed up drug development. Massive Bio combines technology, services and oncology sub-specialist expertise to maximize trial enrollment. Massive Bio is the first company that attacks controlling patient enrollment value chain; Massive Bio does patient identification through direct direct and indirect patient acquisition channels, pre-screening through virtual site, Just-In-Time (JIT) site activation and further analyzes real world data for drug discovery. One of the major differentiating point of Massive Bio is that the Company tackles “last mile” issues for trial enrollment to eliminate site and/or financial considerations of patients. Massive Bio is the go to partner for pharmaceutical companies and CROs to get the right patient at the right time.

Lucy Therapeutics is a biotech company providing effective treatments for neurological diseases start with the mitochondria. The company is offering a differentiated approach to drug discovery by drugging targets associated with early disease pathogenesis. The company's approach can also be expanded to provide new options for treating similar neurologically focused diseases including Parkinson's Disease (PD) and Alzheimer's Disease (AD).

X-Therma is a biotechnology firm that is developing a convergent biopreservation platform to advance regenerative medicine. Using convergent biomimetic nanotechnology, the company is addressing unmet legacy needs in biological product storage. This solution can improve critical biomanufacturing processes, safer transport, and long-term biobanking for advanced cell therapies, IVF, organ transplants, and other rapidly growing regenerative medicine areas.

Surgical Innovation Associates, Inc. (“SIA”, sia.health) is a commercial stage medical device company, committed to raising the standard of care in plastic, reconstructive, and general surgery and lowering systemic costs through “for surgeon, by surgeon” implantable device innovation. Headquartered in downtown Chicago, Illinois, SIA’s proximity to academia and world-leading healthcare institutions has created the ideal ecosystem for the translation of concepts into devices to meet key clinical needs. The company’s flagship product family, DuraSorb® Monofilament Mesh is on the market and indicated for use in reinforcement of soft tissues where weakness exists. DuraSorb® was specifically designed for plastic, reconstructive, and general surgery and is US FDA 510(k) cleared and CE marked. The product is available in multiple sizes, and is part of a growing pipeline of novel medical devices made from commonly-used resorbable polymers.

Cellevolve Bio is a development and commercialization company focused on cell therapies.

Raydiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth. The company develops a low-cost, non-invasive biomedical device to monitor the oxygen levels in fetal blood. It develops and distributes a non-invasive technology that directly monitors a babies' oxygenation during pregnancy. This technology will lead to better patient care and greatly reduce the number of unnecessary cesarean sections. Founded in 2015 by Neil Ray, Raydiant Oximetry is headquartered in Mountain View, California.

Medikabazaar is an online B2B marketspace for medical supplies and equipment. The company is a single point of contact for all product-based needs, enabling medical institutions and individual practitioners alike to cut down on operational costs and making the best global brands available locally, all aided with the miracle that goes by the name of technology. Medikabazaar is connected with more than 50,000 medical establishments, 1,50,000 Independent Practitioners, and have partnered with 13,000+ suppliers all over India including ones in Tier 2, Tier 3 cities, and remoter locations to establish a strong foothold in India. With the power of technology, Medikabazaar organized a haywire market in a country with perhaps the largest and most complex geographical structure in the world for this purpose. Medikabazaar's last-mile delivery system and 26 strategically placed Fulfilment Centers across India enable the company to deliver essential medical supplies to healthcare facilities and help them nurture quality and timely patient care.

Pocket Naloxone's unique dosage form improves naloxone delivery. Its goal is to set prices based on accessibility and affordability. The company contributes to the goal of eliminating opioid overdose deaths.

Stingray Therapeutics is a biotech company that develops immunotherapies to treat various types of cancer. The company was founded in 2018 and is based in Houston, Texas.

Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assist individuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need.

Lyndra Therapeutics is a company that develops medicines for long-term drug release in an oral dose form. The company is developing oral ultra-long-acting and sustained-release therapies for central nervous system (CNS) disorders for broad applicability across multiple therapeutic areas, including approved drugs, allowing the medical community to ensure improved medication adherence and health outcomes while also helping to lower healthcare costs.

Tvardi Therapeutics they are focused on the development of orally delivered, small molecule inhibitors of STAT3. They provide medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases.

Sana Health is an audio-visual neuromodulation device, that provides anxiety relief on-demand - multiple applications in pain and mental health, 2 pivotal studies are underway in Fibromyalgia (FDA designated breakthrough device) and Neuropathic Pain. Anxiety and PTSD trials starting in Q2 2022, DoD grant for PTSD. SOSV, Founders Fund, Noetic Fund, Harmonix, Dreamit, Esplanade, Bridge Builders Collective, Menlo Ventures.

PyrAmes has developed a paper thin, flexible, ultra low power device for non-invasive monitoring of blood pressure

Pison is a human performance company that optimizes cognitive and physiological capability through gesture control. The company offers innovative, non-invasive electroneurography (ENG) algorithms, along with a newly developed sensor array, enabling transformative applications in cognitive enhancement, disease diagnosis and management, and overall quality of life.

AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline to treat patients with few therapeutic options, the Company’s lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of the disease. The Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled and expected to complete in late 2020. Following the lead program, AZTherapies is advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company founded in 2011 and headquartered in Boston, Massachusetts.

StemoniX is a biotechnology company that focuses on stem cell technologies to meet the demands of drug discovery and personalized medicine. StemoniX is revolutionizing the production, growth, and development of stem cell and stem cell technologies. It was founded in 2014 and headquartered in Maple Grove, Minnesota.

Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. It uses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs.

EpiVax Oncology is a provider of a clinical research and development platform intended to offer various type of precision cancer immunotherapies. The company's platform are based on optimal neo-epitopes selected through its proprietary and validated, in-silico, predictive algorithms, enabling clients to address the unmet medical needs that are inadequately addressed by current cancer therapeutic approaches.

NRx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics for the treatment of central nervous system disorders and pulmonary diseases. It addresses life-threatening diseases that often go untreated by researching, developing, and scaling solutions to help people who most desperately need them. The company has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure, and is also developing NRX-100/101 which is the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. In July 2021, the Government of Israel awarded NRx the exclusive worldwide right to develop and market the BriLifeR COVID vaccine developed by the Israel Institute for Biological Research.